Detection of Bladder Cancer Using a Point-of-Care Proteomic Assay

Grossman, H. Barton; Messing, Edward M.; Soloway, Mark S.; Tomera, Kevin M.; Katz, Guy; Berger, Yitzhak; Shen, Yu

doi:10.1001/jama.293.7.810

Cited by 318 publications

(198 citation statements)

References 32 publications

Supporting

Mentioning

180

Contrasting

Unclassified

Order By: Relevance

“…110 In 2005, the performance of the NMP-22 pointof-care (POC) assay was compared with urinary cytology in more than 1000 patients at risk for bladder cancer. 111 The sensitivity and specificity of the NMP-22 POC test was 55.7% and 85.7%, respectively, and no significant difference was found between the NMP-22 POC and urine cytology, both used in conjunction with cystoscopy. The NMP-22 results can be falsely positive as a result of various benign conditions including inflammation, urinary tract infection, and renal calculi.…”

Section: Tumor Biology and Markersmentioning

confidence: 86%

Bladder Cancer in 2010: How Far have We Come?

Jacobs¹,

Lee

Montie

2010

CA: A Cancer Journal for Clinicians

298

275

View full text Add to dashboard Cite

Bladder cancer is the fourth most common cancer and ranks eighth as a cause of death from cancer among men in the United States. Although guidelines assist in treatment, the art of managing bladder cancer, such as the decision to use neoadjuvant chemotherapy and the timing of cystectomy, is still variable. Bladder cancer has a propensity to recur, and with recurrence, a significant number of cases progress, which makes the early detection of high-risk patients imperative. Advances in detection, surveillance, and treatment of bladder cancer are reviewed in this article.

show abstract

Section: Tumor Biology and Markersmentioning

confidence: 86%

Bladder Cancer in 2010: How Far have We Come?

Jacobs¹,

Lee

Montie

2010

CA: A Cancer Journal for Clinicians

298

275

View full text Add to dashboard Cite

show abstract

“…detected at an early stage (Grossman et al, 2005;Messing, 2007;Madeb and Messing, 2008). The 5-year survival mucosa.…”

Section: Resultsmentioning

confidence: 99%

“…A cut-off age of 50 years was chosen because numerous studies have considered ages above this to be a risk factor for bladder cancer (Messing et al, 1987;Alishahi et al, 2002;Madeb and Messing, 2008). The male gender, history of cigarette smoking and gross haematuria are all known to confer a greater risk of bladder cancer (Summerton et al, 2002;Grossman et al, 2005;Lotan et al, 2009). This this study.…”

Section: Resultsmentioning

confidence: 99%

“…Neither is there a method that can safely exclude the presence of bladder cancer in a patient with haematuria, without the use of CE (Khadra et al, 2000;Messing, 2007;Lotan et al, 2009 (Wallace et al, 2002;Gore et al, 2009). Bearing in when detected and treated at an early stage, this usually compels us to perform the investigations as soon as possible (Grossman et al, 2005;Messing, 2007;Madeb and Messing, 2008). This compulsion places a substantial also means that certain patients who really harbour bladder cancer could be diagnosed later simply because they did not receive an early assessment.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Stratifying Patients with Haematuria into High or Low Risk Groups for Bladder Cancer: a Novel Clinical Scoring System

Tan

Shah²,

Ann

et al. 2013

Asian Pacific Journal of Cancer Prevention

View full text Add to dashboard Cite

Haematuria is a common presentation of bladder cancer and requires a full urologic evaluation. This study aimed to develop a scoring system capable of stratifying patients with haematuria into high or low risk groups for having bladder cancer to help clinicians decide which patients need more urgent assessment. This crosssectional study included all adult patients referred for haematuria and subsequently undergoing full urological evaluation in the years 2001 to 2011. Risk factors with strong association with bladder cancer in the study population were used to design the scoring system. Accuracy was determined by the area under the receiver operating characteristic (ROC) curve. A total of 325 patients with haematuria were included, out of which 70 gender, a history of cigarette smoking and the presence of gross haematuria. A scoring system using 4 clinical parameters as variables was created. The scores ranged between 6 to 14, and a score of 10 and above indicated high risk for having bladder cancer. It was found to have good accuracy with an area under the ROC curve of in this study has the potential to help clinicians stratify patients who present with haematuria into high or low risk for having bladder cancer. This will enable high-risk patients to undergo urologic assessment earlier.

show abstract

“…Although the definition of the population at high risk depends on multiple interacting factors, men older than 60 years of age and a smoking history have been traditionally considered to be at high risk (Grossman et al, 2005). The incidence of bladder cancer among men of 60 years of age in the Swedish Family-Cancer Database was around 60 cases per 10 5 person-years.…”

Section: Discussionmentioning

confidence: 99%

Bladder cancer in cancer patients: population-based estimates from a large Swedish study

Bermejo

Sundquist²,

Hemminki

2009

Br J Cancer

View full text Add to dashboard Cite

BACKGROUND: This study quantified the risk of urinary bladder neoplasms in cancer patients taking into account the age at first diagnosis, the gender of the patients and the lead time between diagnoses. METHODS: We used standardised incidence ratios (SIRs) to compare the incidence of bladder tumours in 967 767 cancer patients with the incidence rate in the general Swedish population. A total of 3324 male and 1560 female patients developed bladder tumours at least 1 year after first cancer diagnosis. RESULTS: After bladder and renal pelvis cancers, the SIRs of bladder neoplasms were higher in female than in male patients. Men affected by lung, stomach and larynx tumours belonged to the population at high risk for bladder cancer. Treatment of breast, ovarian and cervical cancers seems to contribute to the subsequent development of bladder neoplasms. Long latencies (16 -25 years) were observed after testicular, cervical and endometrial cancers. Detection bias had an important role after prostate cancer. Chemotherapy with cyclophosphamide and cisplatin, and also radiotherapy, seem to increase the risk of subsequent neoplasms in the bladder. CONCLUSIONS: These population-based results may help urologists to assess the risk of bladder neoplasms in cancer survivors. Our data should guide ongoing studies that investigate the effectiveness of bladder cancer screening in cancer patients.

show abstract

Detection of Bladder Cancer Using a Point-of-Care Proteomic Assay

Cited by 318 publications

References 32 publications

Bladder Cancer in 2010: How Far have We Come?

Bladder Cancer in 2010: How Far have We Come?

Stratifying Patients with Haematuria into High or Low Risk Groups for Bladder Cancer: a Novel Clinical Scoring System

Bladder cancer in cancer patients: population-based estimates from a large Swedish study

Contact Info

Product

Resources

About